Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban vs Aspirin for Non-disabling Cerebrovascular Events
NCT02221102Phase 3Unknown
- Sponsor
- Xijing Hospital
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edoxaban in ischemic stroke and Transient Ischemic Attack (TIA) (3 arms), sponsored by Xijing Hospital. Primary endpoint: Percentage of patients with new stroke (ischemic or hemorrhage) at 90 days. Status: unknown.
02
Drugs
edoxaban
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT02221102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221102.